Status and phase
Conditions
Treatments
About
A Study of Vurolenatide in Adult Patients with Short Bowel Syndrome.
Full description
A Phase 2 study of Vurolenatide in adult patients with SBS. Patients were planned to be dosed in four treatment groups with placebo and/or active Vurolenatide. The study is 13 weeks (3 weeks screening, 4 weeks SC study drug administration, and 6 weeks of follow up). Safety and efficacy will be analyzed.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion Criteria:
Criteria for patient inclusion in this study are as follows:
Key Exclusion Criteria:
Criteria for exclusion from participation in this study are presented below.
Primary purpose
Allocation
Interventional model
Masking
12 participants in 4 patient groups, including a placebo group
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal